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Abstract
Background: High-altitude cerebral edema (HACE) is the severe type of acute mountain sickness (AMS) and life
threatening. A subclinical inflammation has been speculated, but the exact mechanisms underlying the HACE are
not fully understood.
Methods: Human volunteers ascended to high altitude (3860 m, 2 days), and rats were exposed to hypoxia in a
hypobaric chamber (5000 m, 2 days). Human acute mountain sickness was evaluated by the Lake Louise Score
(LLS), and plasma corticotrophin-releasing hormone (CRH) and cytokines TNF-α, IL-1β, and IL-6 were measured in
rats and humans. Subsequently, rats were pre-treated with lipopolysaccharide (LPS, intraperitoneal (ip) 4 mg/kg,
11 h) to induce inflammation prior to 1 h hypoxia (7000 m elevation). TNF-α, IL-1β, IL-6, nitric oxide (NO), CRH,
and aquaporin-4 (AQP4) and their gene expression, Evans blue, Na+-K+-ATPase activity, p65 translocation, and
cell swelling were measured in brain by ELISA, Western blotting, Q-PCR, RT-PCR, immunohistochemistry, and
transmission electron micrography. MAPKs, NF-κB pathway, and water permeability of primary astrocytes were
demonstrated. All measurements were performed with or without LPS challenge. The release of NO, TNF-α, and
IL-6 in cultured primary microglia by CRH stimulation with or without PDTC (NF-κB inhibitor) or CP154,526
(CRHR1 antagonist) were measured.
Results: Hypobaric hypoxia enhanced plasma TNF-α, IL-1β, and IL-6 and CRH levels in human and rats, which
positively correlated with AMS. A single LPS injection (ip, 4 mg/kg, 12 h) into rats increased TNF-α and IL-1β
levels in the serum and cortex, and AQP4 and AQP4 mRNA expression in cortex and astrocytes, and astrocyte
water permeability but did not cause brain edema. However, LPS treatment 11 h prior to 1 h hypoxia
(elevation, 7000 m) challenge caused cerebral edema, which was associated with activation of NF-κB and
MAPKs, hypoxia-reduced Na+-K+-ATPase activity and blood-brain barrier (BBB) disruption. Both LPS and CRH
stimulated TNF-α, IL-6, and NO release in cultured rat microglia via NF-κB and cAMP/PKA.
Conclusions: Preexisting systemic inflammation plus a short severe hypoxia elicits cerebral edema through
upregulated AQP4 and water permeability by TLR4 and CRH/CRHR1 signaling. This study revealed that both
infection and hypoxia can cause inflammatory response in the brain. Systemic inflammation can facilitate
onset of hypoxic cerebral edema through interaction of astrocyte and microglia by activation of TLR4 and
CRH/CRHR1 signaling. Anti-inflammatory agents and CRHR1 antagonist may be useful for prevention and
treatment of AMS and HACE.
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Background
Traveling to high altitude has become very fashionable
in recent years, and ascending too fast or too high may
cause the development of acute mountain sickness
(AMS) due to hypobaric hypoxia. AMS is characterized
by headache and usually accompanied by anorexia, nau-
sea, sleep disturbance, malaise, or a combination of these
symptoms. These relatively benign cerebral symptoms if
not treated or treated inappropriately may develop into
the more lethal high-altitude cerebral edema (HACE)
[1–5]. HACE is characterized by nonspecific patho-
physiological symptoms such as severe headache, loss of
coordination, disturbances of consciousness, psychiatric
changes, and coma [5, 6]. HACE occurrence is not fully
predictable because the underlying molecular-cellular
mechanisms contributing to these changes caused by
exposure to severe high-altitude hypoxia are poorly
understood. Under normobaric conditions, studies of
the physiology and pathophysiology of the blood-brain
barrier (BBB) show that brain edema occurs consequent
to astrocyte swelling and increase in BBB permeability
[7]. In hypobaric hypoxia, these latter pathological ef-
fects depend on upregulation of aquaporin-4 (AQP4) in
astrocytes via activation of corticotrophin-releasing hor-
mone receptor type 1 (CRHR1) following increased local
secretion of corticotrophin-releasing hormone (CRH) in
the brain [8]. This accords with several studies showing
a critical role of upregulated-AQP4 in the formation of
brain edema in various pathological clinical conditions
including ischemia and trauma [9, 10]. Why and how
these changes may progress at high altitude to more se-
vere AMS and HACE is unclear.
HACE usually occurs in unacclimatized individuals
at altitudes over 3000 m and even in seemingly well-
acclimatized mountaineers at extreme altitudes of
7000 m [1]. The sudden onset of HACE remains a
puzzle, and several studies have failed to identify the
reasons. For example, a well-designed series of studies
on humans exposed to hypobaric hypoxia (4875 m)
measured molecular markers of oxidative stress and
brain tissue damage [11, 12]. These studies indicated
there is an increased vascular permeability and in-
flammatory response associated with mild brain
swelling but there is no clear association with
oxygen-derived free radicals. Other factors have been
considered such as genetic predisposition, variation in
hypoxia inducible factor activation, renin-angiotensin
activation, and nitric oxide synthesis, but none are
convincingly associated with pathophysiology of cere-
bral edema [6]. Thus, the mechanisms remain elusive,
and effective strategies for prevention or therapy of
HACE are presently limited. However, it has been
suggested that infection-elicited inflammation is a
trigger for HACE [3, 4, 13].
Previously, few studies have given much attention to
the stress-related central nervous actions of CRH, which
are also activated by systemic inflammation. Interest-
ingly, CRH is locally released in the brain and specific
tissues, and its receptor CRHR1 is known to be involved
in enhancement of the immune and the inflammatory
response [14, 15]. This is in contrast to the systemic
indirect immunosuppressive action of the hormones
[16, 17]. We have reported that CRH/CRHR1 overac-
tivation by hypoxia induces cerebral edema and apop-
tosis [8]. However, whether an infective systemic
inflammatory response interacting with an event in-
duced by hypobaric hypoxia in the brain through
CRH-stimulated activation of microglia to facilitate or
to initiate HACE or not remains unknown.
In the present study, we address this question by first
measuring pro-inflammatory factors and CRH in plasma
of humans and rats to establish the changes that occur
when they are exposed to high altitude. We then set up
a rat model showing an infection-elicited systemic in-
flammation by LPS treatment following hypobaric hyp-
oxia challenge results in onset of HACE, while each
alone fails. We then addressed the underlying mecha-
nisms. The results reveal mechanisms by which hypoxia-
triggered CRH-CRHR1 signaling activates pathways in
brain microglia and show how this is enhanced by in-
flammation leading to the development of cerebral




The human’s study was approved by the Ethics
Committee of the Third Military Medical University
(LKSD2014001). Seventy-four healthy volunteers were
recruited (male, 18–23 years old) in Chengdu, China,
at 540 m altitude, as lowland controls, and a written
informed consent was received by all of the volun-
teers prior to inclusion in the study. Fasting blood
samples from all volunteers were collected in the
morning (07:00–08:00) in Chengdu and the third
morning at Rikaze (3860 m altitude), Tibet Autonomous
Region, China. The Lake Louise Score (LLS) [18] for each
participant was recorded by a clinician. Plasma was ob-
tained by centrifugation and stored at −80 °C.
Animals
Male Sprague-Dawley rats weighing 210 ± 10 g were sup-
plied by the Shanghai Experimental Animal Center, Chinese
Academy of Sciences, Shanghai, China (SCXK2012-0002).
Animals were maintained under constant conditions
(temperature 20 ± 2 °C, humidity 40–60 %, light/dark cycle
12 h) and fed with a standard diet and water. Rats were
housed in the lab for 2 weeks to adapt them to the
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environment before hypoxic experiment. All experiments
were conducted in accordance with the NIH laboratory ani-
mal care guidelines. All protocols concerning animal use
were approved by the Zhejiang University Animal Care and
Use Committee (ZJU201304-1-01-025).
Animal hypoxia treatment
Rats in the hypoxia group were placed in a hypobaric
chamber (Avic Guizhou Fenglei Aviation Armament Co.,
Ltd, China, FLYDWC-50-IIC) and exposed to hypobaric
hypoxia of 7000 m altitude (41.02 kPa, 8.2 % O2) for 1, 4
or 8 h with or without CP154,526 (CRHR1 antagonist,
30 mg/kg, intraperitoneal (ip)) or 5000 m altitude
(54.02 kPa, 10.8 % O2) for 2 days [19]. The normoxia
group was placed in the same chamber set at sea level
(100.08 kPa, 20.9 % O2).
Rats were randomized into six groups. (1) The control
group (n = 12) was injected with 0.9 % saline. (2) The
LPS group (n = 6) was injected with LPS (ip, 4 mg/kg,
body weight) [20–22] for 12 h. (3) The hypoxia group
(n = 6) was exposed to hypoxia (altitude of 7000 m) for
1 h (injected with 0.9 % saline). (4) The LPS + hypoxia
group (n = 12) was injected with LPS for 11 h then ex-
posed to hypoxia for 1 h. (5) The pyrrolidine dithiocar-
bamate (PDTC, NF-κB inhibitor) + LPS + hypoxia group
(n = 10) was pre-treated with PDTC for 0.5 h, then
followed by LPS treatment for 11 h, again followed by
hypoxia for 1 h. (6) The PDTC + hypoxia group (n = 6)
was injected with PDTC for 0.5 h then exposed to hyp-
oxia for 1 h.
Reagents, antibodies and plasmid
LPS was purchased from Sigma (Escherichia coli 055:B5,
USA). IL-1β and TNF-α were from Peprotech (USA).
Evans blue, the NF-κB inhibitor PDTC, the p38 inhibitor
SB203580, the ERK1/2 inhibitor U0126, and the p300
inhibitor curcumin were from Sigma (USA). The JNK in-
hibitor SP600125 was from Cell Signaling Technology
(USA). A fluorescent dye calcein-AM used for live cell im-
aging was from Invitrogen (USA). The antibodies against
p65, p38, phospho-p38, p44/42 MAPK, phospho-p44/42
MAPK, JNK, phospho-JNK, GFAP, and NF-κB were from
Cell Signaling Technology (USA). The AQP4 antibodies
were from Chemicon (USA). CRH was obtained from
Tocris (1151, UK), and CRHR1 antagonist, CP154,526,
was kindly donated by the Pfizer company (USA). The
complementary DNA (cDNA) sequences encoding rat
AQP4 (NM_001142366) were synthesized (Sangon Bio-
tech, Shanghai, China) and then inserted into pmRFP-C1
at the XhoI and EcoRI sites.
Pharmaceutical treatment
For in vivo studies, LPS and PDTC were dissolved in
0.9 % saline. Rats received ip injection of LPS (4 mg/kg),
PDTC (150 mg/kg), CP154,526 (ip, 30 mg/kg), or ve-
hicle. For in vitro studies, astrocytes were treated with
LPS (0.5 μg/ml), IL-1β (0.1 μg/ml) or TNF-α (0.1 μg/
ml), and PDTC (100 μM) for 0.5 h. Microglia were incu-
bated with CRH (10−15 M) for 12 h and CRHR1
(100 nM) antagonist for 0.5 h.
Electron microscopy
Preparation of samples for transmission electron micros-
copy was performed as previously described. Rats were
anesthesized and perfused first by PBS, followed by fix-
ation using 2.5 % (w/v) glutaraldehyde. Samples were
fixed in 2.5 % glutaraldehyde and then postfixed in 1 %
buffered osmium tetroxide, dehydrated in ethanol, and
embedded in epoxy resin. Ultrathin sections (80 nm)
were stained with 2 % uranyl acetate and 3 % lead citrate
and examined in a TECNAI 10 transmission electron
microscope.
siRNA for p300
siRNA duplexes were from GenePharma (Shanghai Gen-
ePharma Co., Ltd, China). Transient transfection of
siRNA or RFP-AQP4 was performed with Lipofectamine
2000 according to the manufacturer’s instructions (Invi-
trogen, USA). Astrocytes were analyzed at 48 h after
transfection of siRNA, and for HeLa cells at 24 h after
transfection of RFP-AQP4. The following siRNA du-
plexes were used: GCCCUGGCAAUAUAUAGAUTT for
p300 and UUCUCCGAACGUGUCACGUTT for nega-
tive control siRNA.
Immunofluorescence staining and fluorescence
microscopy
For brain cortex tissue, 10-μm frozen sections were cut
by cryotome (HM505E, Germany). Immunofluorescence
staining of the tissue sections and cells was performed
as described previously. In brief, tissue sections and as-
trocytes were fixed in 4 % formaldehyde. After being
washed three times in PBS, samples were incubated in
PBS/FBS (PBS, pH 7.4, containing 10 % FBS) to block
nonspecific sites of antibody adsorption. The samples
were then incubated with appropriate primary antibodies
(GFAP, 1:100, p65 1:100) and secondary antibodies
(Alexa Fluor 488- and 545-tagged, 1:500) in 0.1 % saponin.
Images were acquired on a scanning confocal microscope
(LSM 510; Carl Zeiss, Germany) and analyzed with the
LSM 510 software. The number of astrocytes with p65
translocation was scored by the immunofluorescence sig-
nal in the nucleusor cytosol.
Western blotting and cytokine assay
Total protein was extracted from rat brain cortex or as-
trocytes. Sample aliquots of proteins were denatured and
loaded on sodium dodecylsulfate-polyacrylamide gel.
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Proteins were then transferred to a polyvinylidene
difluoride membrane. After being blocked in TBST con-
taining 5 % bovine serum albumin or milk, the mem-
brane was stained with the specific primary antibody
followed by HRP-conjugated goat-anti-rabbit or goat-
anti-mouse antibody. The specific bands were detected
by an ECL Western blotting detection system (Amer-
sham Bioscience, USA). Rat and human TNF-α, IL-1β,
and IL-6 in serum and brain cortex tissue were tested by
ELISA (RayBiotech, USA and Minneapolis, MN, USA)
according to manufacturer’s instructions.
NO assay
In 96-well plates, 50 μl of cell supernatant were added
and reacted with an equal volume of Griess reagent
(Beyotime, China) for 10 min at room temperature in
the dark. Absorbance at 570 nm was determined using a
microplate reader.
Q-PCR and RT-PCR
Total RNA was isolated from cultures with the RNeasy
mini kit (Qiagen, USA), as per the manufacturer’s
protocol. RNA was quantified with a spectrophotometer
(Nanodrop ND-1000, Thermo Scientific, USA). Reverse
transcription of RNA to cDNA was achieved using 2 μg
of total RNA with random hexamer primers using the
TransScript Two-Step RT-PCR SuperMix Kit (TransGen
Biotech, China). Only RNA with a 260/280 ratio of 1.9–
2.0 was used for cDNA synthesis and PCR analysis. Q-
PCR was performed with SYBR premix Ex TaqTM
(Takara, China) on CFX96 Touch™ Real-Time PCR De-
tection System (Bio-Rad, USA). The primers used are
presented as following:
Rat AQP4: (F) TGGTCCTCATCTCCCTCTGCTT, (R)
TGAACCGTGGTGACTCCCAATCC
Rat TNF-α: (F) CCACGCTCTTCTGTCTACTG,
(R)GCTACGGGCTTGTCACTC
Rat IL-1β: (F) CTTCAAATCTCACAGCAGCATC, (R)
GCTGTCTAATGGGAACATCACA
Rat IL-6: (F) AGCCACTGCCTTCCCTAC, (R)
TTGCCA TTGCACAACTCTT
Rat CRH: (F) AAAATGTGGATCCAAGGAGGA, (R)
TAGCCACCCCTCAAGAATGAA
Rat 18s: (F) GTAACCCGTTGAACCCCATT, (R)
CCATCCAATCGGTAGTAGCG
Brain water content
After the end of experiments, rats were sacrificed by de-
capitation and the brain was immediately removed and
weighed and then dried in a thermostatic oven for 48 h
at 120 °C until drying to a constant weight. The dried
brain was re-weighed and the percent brain water
content (BWC) calculated as [(wet weight − dry weight) /
wet weight] × 100 % [8].
Blood-brain barrier permeability
BBB permeability was determined by Evans blue extrava-
sations. Briefly, the dye (2 %, 2 ml/kg) was injected via
the tail vein and circulated for 2 h. Rats were deeply
anesthetized and perfused with saline to remove intra-
vascular dye. The brains were removed and weighed.
The dye in the brain was extracted by incubating in
formamide (1 ml/100 mg) for 24 h at 65 °C, and the
samples centrifuged. The supernatant was measured for
absorbance of Evans blue at 630 nm, and dye concentra-
tions were determined by a standard curve. The concen-
tration of the dye (Evans blus) was expressed as
micrograms of the dye per gram wet weight of the
tissue.
Cell culture and transfections
Astrocyte cultures were prepared from brains of 1-day-
old neonatal Sprague-Dawley rat pups, and cultures were
grown in DMEM containing penicillin, streptomycin,
and 10 % fetal bovine serum, incubated at 37 °C in a
humidified incubator provided with 5 % CO2 and 95 %
air. After 12 days, cultures were shaken at 260 rpm for
12 h at 37 °C to purify the astrocytes. Cell populations
consisted of over 98 % astrocytes as determined by
immunocytochemical examination with anti-GFAP.
HeLa cells and astrocytes were, respectively, cultured
in DMEM supplemented with 10 % fetal bovine
serum (FBS) at 37 °C under 5 % CO2.
Microglia cultures were prepared from the cortex of 1-
day-old Sprague-Dawley rat pups [23, 24]. The isolated
cells were plated in PDL-coated 75 cm2 culture flasks in
minimum essential medium (MEM) containing 10 %
FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin. Cells
were maintained in a humidified atmosphere of 5 % CO2,
95 % air at 37 °C. At 10 days, the microglia were separated
from other cells by washing and shaking for 10 min (with
medium changes at 24 h and then every 3 days). The de-
tached cells were plated on PDL-coated cover slips in a
24-well plate at a density of 1 × 105 per well. After 1 h in-
cubation at 37 °C, the nonadherent cells were removed
and the adherent cells were fed with DMEM containing
10 % FBS for 24 h before further study. The purity of
microglia was consistently >98 %, as determined by flow
cytometry quantification of CD11b+ cells.
Measurement of membrane water permeability
Cells were mounted in a closed chamber on the stage of
an inverted confocal laser scanning microscope (Nikon
TE2000, Japan) in isosmotic, 300 mOsm Hanks, loaded
with 20 μM calcein-AM (Molecular Probes, Invitrogen,
USA) for 5 min at room temperature, and then washed
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with Hanks. The cells were perfused with isosmotic
Hanks and scanned every 1.8 s with excitation at
488 nm. The fluorescent signal was collected at 515–
525 nm from an optical slice within the cell body. Cells
were then subjected to an osmotic shock by switching
the perfusate to a hypo-osmotic, 200 mOsm Hanks. Cell
swelling was monitored as a decrease of calcein fluores-
cence, which occurred due to the dilution of the fluoro-
phore and a reduction in self-quenching. The initial
slope of the fluorescence intensity curve was used to cal-
culate water permeability (Pf) of each cell as described
in detail previously [8, 25].
Statistical analysis
In human data, paired two-tailed t test was used for the
same group, unpaired two-tailed t test was used between
AMS group and no-AMS group, and unpaired two-
tailed t test was used in no-AMS followed by Bonferro-
ni’s multiple comparisons test (p values less than 0.017
were regarded to reflect a significant difference). The
correlations between plasma cytokines and LLS score
were analyzed by using Spearman correlation. In rat
data, comparisons between two groups were analyzed by
an unpaired two-tailed Student’s test; in the case of mul-
tiple mean comparisons, the data were analyzed by one-
way ANOVA or two-way ANOVA (GraphPad Prism 6).
p values less than 0.05 were regarded to reflect a signifi-
cant difference. Data are presented as means ± SD.
Results
Hypoxia induces inflammatory response and CRH release
in humans and rats and correlates with human AMS
Fasting blood samples from all volunteers (n = 74) were
collected at a lowland location and highland location on
the Tibetan plateau. The incidence of AMS was 44.6 %
at day 1, 21.6 %, at day 2, and 14.9 % at day 3, which
gradually reduced with extension of arriving at altitude
of 3860 m (Table 1). At the altitude of 3860 m, blood
SpO2 levels were reduced in all volunteers, but there
was no difference between no-AMS and AMS group
when measured at day 3 (Fig. 1a). Plasma CRH levels
were increased in volunteers with AMS or no-AMS but
were significantly higher in those with AMS at day 3
(Fig. 1b). The correlation between LLS and cytokine
level at day 3 by using Spearman correlation analysis
showed there was a positive correlation between LLS
and cytokine levels of TNF-α, IL-1β, and IL-6 at high
altitude (r = 0.3, p < 0.05; r = 0.4, p < 0.001; r = 0.39, p <
0.001, respectively, Fig. 1c) but no correlation at low
land. TNF-α, IL-1β, and IL-6 levels in the plasma of all
volunteers were significantly increased at altitude of
3860 m at day 3 (#P < 0.05, ###P < 0.001, respectively,
Fig. 1d–f ), and the increases were significantly higher in
volunteers with AMS than no-AMS. At altitude of
3860 m, at day 3, plasma TNF-α, IL-1β, and IL-6 levels
were significantly higher in the AMS groups than in the
no-symptoms group (A) within the no-AMS groups
(Table 2, E vs A). In addition, the IL-6 levels in the
headache-only group (B) were significantly higher than
those in the no-symptom group (A) (+p = 0.008, B vs A).
Headache + two symptoms group (E) of AMS groups
was higher than in the other symptoms group (D) (&p =
0.02, D vs E); moreover, IL-1β levels were higher (in-
creased trend) in headache + one symptom group (C)
and other symptoms group (D) than in the no-symptom
group (A) ($p = 0.013 and @p = 0.03; C vs A and D vs A),
suggesting that high-altitude hypoxia-increased plasma
levels of pro-inflammatory factors (TNF-α, IL-1β, and IL-
6) are associated with AMS. Interestingly, exposure of rats
to hypobaric hypoxia (10.8 % O2, at altitude of ~5000 m)
for 2 days increased plasma levels of CRH, TNF-α, IL-1β
(Fig. 1g–i), and hypoxia (7000 m, 8 h)-increased plasma
levels of TNF-α and IL-1β were blocked by CRHR1 antag-
onist (CP154,526) (Fig. 1j, k), suggesting that hypobaric
hypoxia induces an immune-inflammatory response in
humans and rats, which is positively associated with ac-
tivation of CRH/CRHR1 and with the development of
AMS in humans.
Peripheral LPS-induced systemic inflammation promotes
the development of brain edema in rats under hypoxia
To investigate the potential role of systemic inflammation
in the development of brain edema under hypoxia, four
groups of rats were exposed to normoxia or hypoxia
Table 1 Comparison of AMS and no-AMS (total n = 74) volunteers at an altitude of 3860 m
day 1 day 2 day 3
AMS 33/74 (44.6 %) 16/74 (21.6 %) 11/74 (14.9 %)
Headache 33/33 (100 %) 16/16 (100 %) 11/11 (100 %)
No-AMS 41/74 (55.4 %) 58/74 (78.4 %) 63/74 (85.1 %)
Headache only 8/41 (19.5 %) 7/58 (12.0 %) 6/63 (14.6 %)
Headache + one symptom 9/41 (21.9 %) 9/58 (15.5 %) 3/63 (4.8 %)
Others (no-headache) 12/41 (29.2 %) 15/58 (25.9 %) 14/63 (22.2 %)
No symptom 12/41 (29.2 %) 27/58 (46.6 %) 40/63 (63.5 %)
Note: % indicates the incidence of symptom
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(altitude of 7000 m) in a hypobaric chamber: one nor-
moxic group, one hypoxic group, one LPS group (ip,
4 mg/kg) under normoxia, and one LPS + hypoxia group.
First, hypoxia exposure for 4 or 8 h markedly increased
TNF-α and IL-1β levels in both plasma and brain cortex
(Fig. 2a, b) and TNF-α mRNA and IL-1β mRNA expres-
sions in brain cortex, compared with control or hypoxia
for 1 h group (Fig. 2c). Second, a single injection of LPS to
rats for 0, 3, 6, 12 h, induced systemic pro-inflammatory
response under normoxia, showing significantly increased
TNF-α and IL-1β levels in both plasma and brain cortex
(Fig. 2d, e) compared with control but did not increase
BWC (Fig. 2f). Third, rats were exposed to hypobaric hyp-
oxia for 1 h, and this did not increase the cytokine levels
or BWC but reduced Na+-K+-ATPase activity (Fig. 2g–i, k).
However, rats pre-treated with LPS alone for 11 h followed
by 1 h hypobaric hypoxia (7000 m) (LPS + hypoxia) showed
markedly increased TNF-α and IL-1β levels in the plasma
and brain cortex (Fig. 2g, h) and increased BWC (Fig. 2i) as
well as Evans blue extravasations (Fig. 2j), compared with
LPS injection alone, suggesting LPS + hypoxia induces BBB
disruption and plays a role in induction of BWC (vasogenic
edema). In addition, hypoxia exposure alone (altitude,
7000 m, 1 h) significantly decreased Na+/K+-ATPase activ-
ity in rat brain cortex (Fig. 2k) and caused water influx into
brain cells because of hyperosmotic pressure in cells, re-
vealed by further swelling of astrocytes. LPS + hypoxia sim-
ultaneously induced cytotoxic and vasogenic edema, which
was supported by the transmission electron microphoto-
graph (Fig. 2l), showing an enlarged perivascular space of
astrocyte endfeet in rat cortex compared with single LPS or
hypoxia treatment. Moreover, water overloaded rats by ip
20 % ddH2O showed increased BWC, which became more
severe when challenged by LPS, indicating LPS played a
role in induction of brain edema but required extracellular
hyposmolarity (Additional file 1: Figure S1A). GFAP-
Fig. 1 High-altitude hypoxia induced increased levels of TNF-α, IL-1β, IL-6, and CRH in humans and rats. a Human SpO2 was measured by fingertip
pulse oximeter at low and high altitudes. b The levels of CRH in plasma of all human volunteers was determined by ELISA (n = 74). c The correlation
between LLS score data and cytokines (TNF-α, IL-1β, and IL-6) level at high altitude by Spearman correlation analysis. d–f The levels of TNF-α, IL-1β,
and IL-6 in plasma of all human volunteers was determined by ELISA (n = 74). ***P < 0.001 compared with control (low altitude, 540 m); #P < 0.05,
###P < 0.001 compared with no-AMS group at high altitude (3860 m). g–i The rats in hypoxia group were exposed to hypoxia at altitude of 5000 min a
hypobaric chamber for 2 days. The levels of CRH, TNF-α, and IL-1β in plasma were measured (n = 7). j, k Hypoxia-increased TNF-α and IL-1β levels in
plasma were blocked by CRHR1 antagonist CP154,526 (n = 7). **P < 0.01; ***P < 0.001 compared with control, &P < 0.05 (hypoxia vs hypoxia + CRHR1
antagonist); the data are presented as mean ± SD
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labeled astrocytes presented thicker foot processes in
LPS + hypoxia rats (Additional file 1: Figure S1B). LPS +
hypoxia-induced swellings of perivascular astrocyte endfeet
(Fig. 2l) were also attenuated by PDTC (Additional file 1:
Figure S1B, last one). These results suggest that the
increase of cerebral vascular permeability and brain
edema is a result of a combination of LPS-increased
pro-inflammatory cytokines and hypoxia-increased ves-
sel permeability together with BBB disruption and
hypoxia-reduced Na+/K+-ATPase activity.
LPS increases expression of AQP4 and AQP4 mRNA in rat
cortex and astrocytes and water permeability of
astrocytes
Considering the essential role of AQP4 in the formation
of cytotoxic edema, we measured its expression in brain
cortex and astrocytes and found that hypoxia (7000 m
elevation, 4 or 8 h) increased AQP4 mRNA in cortex
(Fig. 3a), and LPS (4 mg/kg, 8 or 12 h) also markedly in-
creased its expression (Fig. 3b). Furthermore, LPS 12 h +
hypoxia 1 h significantly increased AQP4 mRNA in
cortex, compared with control, but the increase was no
different to the increase caused by LPS alone. Hypoxia
1 h alone did not cause any significant effect compared
to control (Fig. 3c). AQP4 protein and mRNA were
time-dependently enhanced in brain cortex and astro-
cytes (Fig. 3d–f ) after LPS treatment. In addition, AQP4
mRNA increased after TNF-α and IL-1β challenge for
8 h (Fig. 3g). Moreover, LPS also increased water perme-
ability in astrocytes (Fig. 3h). To demonstrate that the
highly expressed AQP4 was associated with enhanced
water permeability of astrocytes, RFP-tagged AQP4 was
transfected into HeLa cells and the membrane perme-
ability was measured after hypo-osmotic challenge. This
showed that the cell membrane permeability was posi-
tively correlated with AQP4 expression (Additional file 1:
Figure S2A). Inhibitors of protein synthesis (CHX) and
transcription (ActD) abolished the LPS-increased mem-
brane permeability (Additional file 1: Figure S2B). The in-
crease in BWC following LPS + hypoxia was also
prevented by a PDTC or MG132 (Additional file 1: Figure
S2C). These data suggest that stimulating AQP4 expres-
sion by pro-inflammatory factors increases water perme-
ability in astrocytes.
Inflammatory factors-induced increase of AQP4
expression through NF-κB and MAPK pathway
A clear translocation of p65 from cytoplasm to the
nucleus was found in LPS, TNF-α, or IL-1β treated
astrocytes compared with untreated astrocytes. PDTC
pre-treatment prevented p65 translocation (Fig. 4a, b),
inhibited AQP4 protein expression and blocked the in-
crease of water permeability in the astrocytes (Fig. 4c, d),
showing NF-κB involvement. We further demonstrated
that LPS, TNF-α, or IL-1β all induced the phosphoryl-
ation of cellular signal regulated protein kinase (ERK)1/
2, p38, and p300 activity (acetylation H3 and H4) (Fig. 4e
and Additional file 1: Figure S3A). In addition, the inhib-
itors of p38 (SB203580), ERK1/2 (U0126), p300 (Curcu-
min, Cur), and si-p300 (Fig. 4f, Additional file 1: Figure
S3B-D) blocked LPS-stimulated increase of AQP4
mRNA. Inhibitors of JNK (SP600125) did not change
AQP mRNA and membrane permeability. The inhibitors
of ERKs, p38, and p300 could also reduce the increase of
astrocyte membrane permeability caused by LPS 12 h
(Fig. 4g). Therefore, MAPKs (ERKs and p38) and p300
play important roles in the increase of AQP4 and astro-
cyte membrane permeability induced by inflammation.
Table 2 Cytokines level at 540 m and at 3860 m (hypoxia)
TNF-α IL-1β IL-6 (pg/ml) N
Symptoms 540 m 3860 m 540 m 3860 m 540 m 3860 m 74
No-AMS:
A (no symptom) 15.09 ± 0.51 (3.22) 19.39 ± 1 (6.33)*** 3.43 ± 0.63 (2.1) 5.07 ± 0.98 (3.24)*** 7.51 ± 0.36 (2.28) 11.43 ± 0.8 (5.06)*** 40
B (headache only) 17.57 ± 2.25 (5.52) 22.7 ± 2.83 (6.94)* 4.1 ± 0.81 (1.98) 7.23 ± 1.01 (2.48) 8.57 ± 0.98 (2.4) 18.27 ± 3.65 (8.94)*,+ 6
C (headache + 1
symptom)
16.64 ± 3.24 (5.61) 20.31 ± 4.55
(7.88)
4.32 ± 0.37 (0.64) 10.22 ± 2.51 (4.35)$ 7.85 ± 1.23 (2.13) 15.2 ± 2.59 (4.48) 3
D (other symptoms) 15.46 ± 1.18 (4.4) 20.96 ± 1.32
(4.92)***
4.52 ± 0.58 (2.16) 7.12 ± 0.55 (2.07)***,@ 7.47 ± 0.57 (2.12) 13.32 ± 1.49 (5.57)**,& 14
AMS:
E (headache + 2
symptoms)
15.23 ± 1.24 (4.11) 25.59 ± 2.84
(9.42)**, #
3.34 ± 0.46 (1.51) 7.65 ± 0.85 (2.83)***,# 8.14 ± 0.76 (2.53) 20.62 ± 2.5 (8.29)***,### 11
Values are presented means ± SE (SD)
*P < 0.05; **P < 0.01; ***P < 0.001 compared with cytokines level of same group at 540 m
#P < 0.05; ###P < 0.001 compared with A group (TNF, P = 0.013; IL-1, P = 0.02; IL-6, p = 7.6 × 10−5) at 3860 m
+P < 0.017; compared with A group at 3860 m by Bonferroni’s multiple comparisons test after correction (IL-6, A vs B P = 0.008)
$P < 0.017, trends by 0.017 < @P < 0.05 (IL-1, A vs C, P = 0.013; A vs D P = 0.03)
&P < 0.05 compared with E group (D vs E, P = 0.02) at 3860 m
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CRH stimulates microglia and triggers immune-inflammatory
response under hypoxia
To determine the effects of CRH on cerebral microglia,
the release of TNF-α, IL-6, and NO from cultured pri-
mary microglia was measured. We found that CRH chal-
lenge for 24 h induced TNF-α, IL-6, and NO release,
and CRH + LPS induced further increase of these cyto-
kines compared with CRH and LPS alone (Fig. 5a, b).
The increase in NO release elicited by CRH was blocked
by CRHR1 antagonist (CP 154,526) (Fig. 5c) and by
PKA pathway inhibitor (insert in Fig. 5c). CRH +
LPS-induced release of NO was reduced by CRHR1
Fig. 2 Systemic inflammation facilitates the onset of brain edema under transient hypoxia. a, b TNF-α and IL-1β level in serum and in brain cortex
of rats were tested after hypoxia exposure (1–8 h) and increased after 4 h. c Hypoxia-increased TNF-α and IL-1β mRNA expression in brain cortex
(n = 6). *P < 0.05; **P < 0.01; ***P < 0.001 compared with control. &P < 0.05; &&P < 0.01; &&&P < 0.001 (4 h hypoxia vs 1 h hypoxia). d, e TNF-α and IL-
1β levels in serum and cortex of rats were measured by ELISA and increased, following the LPS treatments indicated (n = 6). *P < 0.05; **P < 0.01;
***P < 0.001 compared with control. f Brain water content (BWC) was determined by wet/dry weight ratio at the time points indicated after LPS
treatment (n = 6–12). g, h TNF-α and IL-1β levels in serum and cortex of rats were measured by ELISA and increased, following LPS or hypoxia
alone or combination of both treatments indicated (n = 6). *P < 0.05; **P < 0.01; compared with control. +P < 0.05; ++P < 0.01, hypoxia + LPS vs
hypoxia. i BWC was determined by wet/dry weight ratio after LPS, hypoxia or both (n = 6–12), ***P < 0.001 compared with control, +++P < 0.001,
compared with LPS or hypoxia alone. j BBB permeability was determined by detecting the extravasations of Evans blue dye (n = 8). **P < 0.01
compared with control, ++P < 0.001, compared with LPS or hypoxia alone. k Na+/K+-ATPase activity in brain cortex was measured following the
indicated treatments (n = 6). **P < 0.01 compared with control, ++P < 0.01, compared with hypoxia or hypoxia + LPS. All data are presented as
mean ± SD. l Representative transmission electron micrographs of perivascular astrocytes and mitochondria. Scale bar, 1 μm, arrow indicates
enlarged astrocyte foot processes
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antagonist CP154,526 (Fig. 5c). Increased IL-6 protein
in brain cortex after hypoxia or LPS 8 h was blocked
by CRHR1 antagonist (CP154,526) (Fig. 5d). In vivo,
hypoxia (1or 8 h at altitude of 7000 m) also significantly
increased CRH, TNF-α, and IL-6 mRNA expression in rat
brain cortex (Fig. 5e) and this hypoxia-increased plasma
CRH level in a time-dependent manner (Fig. 5f). These
data evidence that both CRH and LPS have a stimulating
effect on cytokine release in cerebral microglia.
Discussion
HACE is a severe form of AMS; untreated severe AMS
or treated non-appropriately may progress to HACE. In-
creasing numbers of papers suggest that an inflamma-
tory response is associated with AMS and HACE, but
the exact mechanisms are less explored and the inflam-
matory view remains speculative. This study attempted
to provide credible evidence for a pathogenic role of in-
flammatory mediators in AMS and more particularly in
HACE. The experiments showed that high-altitude hyp-
oxia induces an increase of circulating cytokines TNF-α,
IL-1β, and IL-6 in humans. We also found that the levels
of TNF-α and IL-1β were increased in rat plasma and
brain cortex (Figs. 1 and 2), and their gene expression
was increased in cortex (Fig. 2) and increased in a time-
dependent manner in whole blood by simulated altitude
hypoxia (data not shown), suggesting an enriched way
for increasing their plasma levels. More importantly, the
plasma stress peptide, CRH levels, increased significantly
in both human and rats. This was accompanied by posi-
tively associated upregulated pro-inflammatory factors
and was blocked by CRHR1 antagonist. Significantly, the
study showed, for the first time, that the magnitude of
the pro-inflammatory factors of TNF-α, IL-1β, and IL-6
in humans was positively correlated with the develop-
ment of the symptoms of AMS (Fig. 1c). In accord with
these results, other studies have suggested that hypoxia-
elicited neurohormonal changes ultimately lead to in-
creased cerebral blood flow, enhanced permeability of
the BBB, and cerebral edema [1, 2, 8, 26–28]. Further-
more, it is known that hypoxia increases levels of circu-
lating pro-inflammatory cytokines and ROS markers,
with vascular leakage, suggesting that these changes may
be the causes of cerebral edema observed in volunteers
at high altitude [29–33]. The new findings of the present
study allow us to propose a novel pathological theoret-
ical perspective for AMS and even HACE, which is that
hypoxia-activated CRH and its CRHR1 signaling play a
Fig. 3 LPS and cytokines increase AQP4 mRNA and protein expression in the brain cortex and astrocytes, and LPS increases water permeability
of astrocytes. a The expression of AQP4 mRNA in brain cortex tested by Q-PCR following hypoxia exposure for the time points indicated (n = 6).
**P < 0.01, ***P < 0.001 compared with control; &&P < 0.01 (hypoxia 4 h vs hypoxia 1 h). b The expression of AQP4 mRNA in the brain cortex of rats
determined by Q-PCR following injection of LPS for the time points indicated (n = 6). ***P < 0.001 compared with control. c Hypoxia + LPS and
LPS increased AQP4 mRNA expression in brain cortex (by Q-PCR), ***P < 0.001 compared with control. d AQP4 protein expression in brain cortex
was detected by western blot after LPS treatment at the time points indicated (n = 6). ***P < 0.001compared with control, +++P < 0.001 vs LPS
10 h. e AQP4 mRNA expression and f AQP4 protein expression in astrocytes were detected by RT-PCR and western blot after LPS challenge
(n = 3). *P < 0.05; **P < 0.01; ***P < 0.001, compared with control; ++P < 0.01, compared with 8 h. g AQP4 mRNA expression in astrocytes was
determined by RT-PCR after LPS, TNF-α, or IL-1β treatment for 8 h (n = 3). **P < 0.01, ***P < 0.001, compared with control. h Water permeability
of cells increased by LPS challenge (n = 100). ***P < 0.001, compared with control. All the data are presented as mean ± SD
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key role in induction of a pro-inflammatory response
and AMS. Others have also linked cytokine activation
with effects on brain function. For example, in a recent
review, it was suggested that hypoxia of high altitude
and its association with increased TNFα, IL-1β, and IL-6
might explain sleep disturbances, but a link with AMS
Fig. 4 Inflammation induced increased AQP4 expression via the NF-κB and MAPKs pathway. a Astrocytes pre-treated with or without PDTC were treated
with LPS, TNF-α, or IL-1β for 2 h, followed by staining with specific p65 antibody (n= 3). b p65 translocation into cell nuclei (%) after treatment with LPS,
TNF-α, or IL-1β for 2 h. c AQP4 protein levels in astrocytes treated with LPS for 12 h after pre-treatment with or without PDTC (n= 3). d Water permeability
of cells after LPS or LPS + PDTC treatment (n= 100). **P< 0.01; ***P< 0.001 compared with control; ##P< 0.01;###P< 0.001 compared with LPS 12 h. e
Phosphorylated levels of ERKs and p38 in astrocytes treated with LPS, TNF-α, or IL-1β for 0.5 h were increased (n= 3). ***P< 0.001, compared with control.
f AQP4 mRNA changes measured by RT-PCR in astrocytes treated with LPS for 8 h after pre-treatment with p38 inhibitor, ERK1/2 inhibitor, JNK inhibitor
(n= 3). ***P< 0.001 compared with control; ##P< 0.01 compared with LPS treatment. gWater permeability changes of astrocytes pre-treated with p38
inhibitor, ERK inhibitor, JNK inhibitor, p300 inhibitor, or transfected with p300 siRNA then exposure to LPS for 12 h (n= 100). ***P< 0.001 compared with
control; ###P< 0.001 compared with LPS 12 h. All the data are presented as mean ± SD
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and HACE [34] was not implied. We are also aware
there is report that AMS susceptibility seems not related
to an exaggerated inflammatory response [33]. This may
associate with the group size (20 vs 74 in the present
study), age (25–31 years old vs 18–23 years old), gender
(men + women vs men), the duration (4.9 h vs 3 days),
and altitude (4875 vs 3860 m).
It is clear from the present study that plasma cytokine
levels on human exposure to high altitude were in-
creased and positively correlated with LLS score (Fig. 1c,
3860 m). The level of inflammatory markers (plasma
TNF-α, IL-1β, IL-6) showed a significant separation be-
tween the no-symptoms group and AMS group (Table 2).
Therefore, we consider that significant high plasma level
of cytokines TNF-α, IL-1β, and IL-6 could be valuable
for evaluating AMS compared to no-AMS in humans
exposed to high altitude. In addition, since it is
known that the development of AMS largely associ-
ates with the elevation, speed of ascent, and the dur-
ation at the altitude, these would make the changes
in cytokines flexible.
AMS and HACE are part of a spectrum of altitude
illness. AMS can develop into cerebral edema when
treated improperly or if a person suffers more severe
hypoxia [1–5]. Both forms of high-altitude illness are ex-
acerbated when combined with infection-elicited inflam-
mation. Therefore, we studied the impact of hypoxia
with or without infection-elicited immune-inflammation
on the onset and extent of cerebral edema during transi-
ent or prolonged hypoxia. For this, we used the rat as a
model because ethically we could not take human volun-
teers to an altitude at which there might be a greater
chance of inducing HACE without good medical and
emergency evacuation facilities as well as a plentiful sup-
ply of oxygen. The rat also gave us the opportunity to
look at the effects of exposure at different altitudes and
for different durations using our well-designed automat-
ically controlled hypobaric chamber with which we have
much experience. The rat model enabled us to examine
the interaction of signaling pathways involved in hypo-
baric hypoxia and infection induced inflammation. For
the present purpose, we established a rat inflammation
model using ip injection of LPS (4 mg/kg, BW) to mimic
an infection and found that LPS significantly increased
TNF-α and IL-1β levels in the plasma and brain cortex.
The experiment also revealed that LPS or pro-
Fig. 5 CRH stimulates microglia and triggers an immune-inflammatory response. a, b Increase in TNF-α and IL-6 release in cultured primary
cortical microglia induced by CRH or LPS or CRH+LPS challenge for 24 h. **P < 0.01, compared with control, #P < 0.05; ##P < 0.01, LPS + CRH vs
LPS. c Increase in NO production in cultured primary cortical microglia challenged by CRH, LPS or CRH+LPS. **P < 0.01, compared with control;
&P < 0.01, compared between LPS + CRH and LPS; @@P < 0.01 compared between CRH + LPS and CRH + LPS + CP154,526; ###P < 0.01, compared
between CRH and CRH + CP154,526. CRH stimulated increased NO production, was blocked by PKA inhibitor (inset). ***P < 0.001 compared with
control, +++P < 0.001 compared between CRH and CRH + PKA inhibitor. All the data are presented as mean ± SD. d Hypoxia and LPS increased
IL-6 protein levels in brain cortex. Increased IL-6 protein in rat brain cortex following either hypoxia or LPS (8 h) was blocked by CRHR1 antagonist,
n = 6, **P < 0.01 compared with control, ++P < 0.01 compared between hypoxia and hypoxia + CP154,526, ##P < 0.01 compared between LPS and
LPS + CP154,526, the data are presented as mean ± SD. e Hypoxia stimulated expression of mRNAs of CRH, TNF-α, and IL-6 in brain cortex (n = 6)
**P < 0.01, compared with control, the data are presented as mean ± SD. f Hypoxia-increased CRH release in circulation **P < 0.01, compared with
control; ++P < 0.01, compared between hypoxia 2 and 8 h, the data are presented mean ± SD
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inflammatory factors increase AQP4 and AQP4 mRNA
through TLR4 signaling via MAPKs and NF-κB in cortex
and astrocytes, shown by these pathways being blocked
by selective antagonists. Associated with this signaling
there is increased water permeability of astrocytes via ac-
tivated NF-κB when charged by hypotonic solution. It
would therefore seem that inflammation at some level
provokes the onset of cerebral edema. However, LPS
alone, that is without hypoxia, did not induce brain
edema, which clearly indicates that both stimuli are
needed for brain swelling. This may of course depend on
the dosage and time course, the method of treatment
with LPS or, perhaps, the animal strain used. For ex-
ample, in other studies, 250 μg (0.5 ml) or 4 mg/kg of
LPS given ip did not induce cerebral edema in adult rats
[20–22, 35], whereas microinjection of LPS directly into
the substantia nigra of rat brain (2 μl, 1 mg/ml) or injec-
tion of LPS in mice (ip, 0.15 mg/mouse) induced brain
edema [36]. In humans, inflammation can induce cere-
bral edema in stroke or trauma [37, 38], but importantly,
these are accompanied by local hypoxia. In accord, cere-
bral edema is observed with other ischaemic hypoxic
disease. Hence, the balance of evidence suggests that
inflammation has an essential pathogenic significance in
brain edema.
Using the rat model in the present study has revealed
some of the factors and mechanisms that are a likely
cause of the cerebral edema, associated with hypoxia
and inflammation. Clearly duration of stress is import-
ant. Thus, hypoxia (7000 m, ~8.2 % O2) for 1 h reduced
Na+-K+-ATPase activity (Fig. 2) but did not induce a
pro-inflammatory response; however, hypoxia for 4 and
8 h induced inflammation and cerebral edema (Fig. 2).
Moreover, a more severe challenge, LPS + hypoxia (LPS
for 11 h prior to 1 h hypoxia) resulted in cerebral edema.
This appeared to be due to LPS-triggered cytotoxic
astrocyte swelling caused by activating AQP4 and by
hypoxia-reduced Na+-K+-ATPase. This allowed in-
creased water influx into cells. Hence, LPS, combined
with hypoxia-induced BBB vasculature leakage, enhances
edema. In accord with this in humans, hypoxia has been
shown to increase cerebral blood flow in the human
brain as measured by single photon emission computed
tomography [39]. In rats, inflammation causes astrocyte
swelling with disruption of the BBB [40–42]. Thus, there
is a clear parallel between the experimental data in rats
and that seen in humans. Importantly, from the rat ex-
periments, we can gain an idea of the cellular mecha-
nisms that may lead to HACE. For example, prolonged
hypoxia increases the cytokine (Fig. 2g–i) and CRH
Fig. 6 Integrated results of this study to diagrammatically show how LPS-induced systemic inflammation facilitates the onset of cerebral edema
under short-term hypoxia in rats by (1) LPS-induced pro-inflammatory pathway which activates AQP4 and contributes to water permeability of
astrocytes via TLR4 signaling MAPKs and NF-κB, (2) short-term hypobaric hypoxia which reduced Na+-K+-ATPase activity resulting in water inflow
in astrocytes, (3) LPS + hypoxia-induced leakage of BBB resulting in vasogenic edema. All together, these factors contribute to brain edema. Under
prolonged hypoxia, systemic inflammation may worsen the cerebral edema by (1) LPS plus hypoxia-induced astrocyte cytotoxic swelling;
(2) LPS plus hypoxia-activated cortical microglia release of cytokines, which further stimulate astrocyte swelling; and (3) hypoxia further
reducing Na+-K+-ATPase activity, and LPS + hypoxia triggering leakage of BBB. This mechanism in rats may describe the onset and deterioration of
HACE in human
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levels in plasma and enhances CRH, IL-6, and TNF-α
mRNA expression in brain (Fig. 5e, f ). In addition, hyp-
oxia or LPS can upregulate IL-6 protein in the brain cor-
tex (Fig. 5d). Also CRH or LPS, particularly CRH + LPS,
stimulate TNF-α, IL-6, and NO release in cultured pri-
mary microglia via CRH-activated CRHR1 signaling
PKA. These data suggest that both an infection- and
hypoxia-elicited inflammatory response can summate to
worsen cerebral edema through interaction between as-
trocytes and microglia. This depends on TLR4-initiated
MAPKs and NF-κB and CRHR1-initiated cAMP/PKA
signaling to activate AQP4 and eventually induce cyto-
toxic and vasogenic edema.
We have recently reported that in rats, hypoxia-
induced overactivation of CRHR1 and AQP4 produces
cerebral edema tested by magnetic resonance imaging
(MRI). This action is mediated by hypoxia activating
local CRH neurons in cortex through CRHR1 initiating
cAMP/PKA and Ca2+/PKCε signaling which triggers
AQP4 phosphorylation and gene expression in astro-
cytes to contribute to brain edema [8]. The protein kin-
ase G (PKG) pathway is not directly involved in
activation of AQP4 in astrocytes as hypoxia-induced
HIF-1α expression does not cause iNOS expression and
NO release in astrocytes [8]. However, we showed in
present study that NO is released and supplied by
hypoxia-activated microglia (Fig. 5), which implies that
the PKG pathway also contributes to astrocyte swelling.
These data are summarized in Fig. 6f and showed how
an interplay between astrocyte and microglia through
TLR4 and CRHR1 signaling pathways work during infec-
tion and hypoxia to cause cerebral edema.
Conclusions
The present study shows that in humans and rats, hypo-
baric hypoxia causes an inflammatory response with
cytokine release, which positively correlates to severity
of AMS syndrome in humans and with activation of
CRHR1 in central microglia and peripheral tissues in
rats. The experiments have also clarified the mechanisms
that lead to cerebral edema associated with hypobaric
hypoxia and provide for the first time clear evidence for
a facilitatory role of inflammation. These results suggest
that the CRH receptor CRHR1 might be a promising tar-
get for prevention and therapy of AMS and HACE and
enable development of novel therapeutic interventions
with wider clinical potential.
Additional files
Additional file 1: Figures S1–S3. Figure S1. (A) Brain water content
was measured following injection of rats with LPS (ip) for 12 h, H2O-
injection for 0.5 h or both (n = 6). ***p < 0.001 compared with control;
###P < 0.001 compared between 20 % ddH2O and 20 % ddH2O + LPS
treatment. (B) Immunohistochemical fluorescence of GFAP in the cortex
of rats treated as indicated. Scale bar, 50 μm. Representative transmission
electron micrographs of perivascular astrocytes and mitochondria. Scale
bar, 1 μm (last one). Figure S2. (A) Fluorescence intensity of RFP-AQP4
and water permeability were measured in transfected RFP-AQP4 HeLa
cells (n = 60). (B) Astrocytes were pre-treated with CHX or ActD or un-
treated. The water permeability of astrocytes was determined after 12 h
LPS stimulation (n = 100). ***P < 0.001 compared with control; ###P < 0.001
compared with LPS 12 h. (C) Brain water content was determined by dry-
wet weight method at the indicated time points and under the indicated
conditions (n = 6–12). ***p < 0.001 compared with control; ###P < 0.001
compared with LPS + hypoxia, all data are presented as mean ±SD.
Figure S3. Inflammation induced AQP4 high expression through MAPK
pathway. (A) Astrocytes were treated with LPS as indicated time, and the
phosphorylation levels of ERKs and p38 were tested by western blot
using anti-phospho-ERK or anti-phospho-p38 antibodies (n = 3). *P < 0.05;
**P < 0.01;***P < 0.001 compared with control. (B) Acetylation levels of H3
and H4 in astrocytes were determined by western blot as indicated time
after LPS treatment (n = 3). ***P < 0.001 compared with control, Student’s
t test. (C,D) Increased-AQP mRNA by LPS in astrocytes were be blocked
by Cur, si-p300. ***P< 0.001 compared with control, ###P< 0.001 compared
with LPS or si control, all data are presented as mean ±SD. (DOC 1687 kb)
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